Member Center

WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the medtech association, made the following comment on President Trump’s nomination of Dr. Heidi Overton to serve as FDA commissioner. 

WASHINGTON, D.C. – AdvaMed today announced that Juan Carlos “JC” Scott has been appointed Chief Strategy Officer and Executive Director of AdvaMed Accel, a newly created leadership position focused on accelerating engagement with emerging medical technology companies and strengthening AdvaMed’s role at the center of the innovation ecosystem.

Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.

Experience the future of health care at the 2026 Medtech Showcase and Reception on Capitol Hill. Join AdvaMed® on September 16 for an interactive event featuring more than 25 medtech companies demonstrating breakthrough technologies that are transforming patient care. See innovative medical devices firsthand, connect with industry leaders and policymakers, and discover how medtech innovation is improving and saving lives.

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today expressed strong support for the draft Medical Device User Fee Amendments (MDUFA) VI agreement at an FDA public hearing.

Read Gateways to Health, a special publication exploring how medical technology improves patient care, expands access, and lowers healthcare costs.

WASHINGTON, D.C.—AdvaMed, the Medtech Association, today welcomed next steps in the Medical Device User Fee Amendments reauthorization process following clearance by the White House Office of Management and Budget of the draft MDUFA VI agreement. 

WASHINGTON—Scott Whitaker, president and CEO of AdvaMed, the largest trade association representing medtech innovators, posted his statement on LinkedIn regarding the nomination of Chris Klomp as deputy secretary of the Department of Health and Human Services.